相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Congenital Conditions of Hypophosphatemia in Children
Erik Allen Imel
CALCIFIED TISSUE INTERNATIONAL (2021)
Osteoarthritis, Osteophytes, and Enthesophytes Affect Biomechanical Function in Adults With X-linked Hypophosphatemia
Amy Steele et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Dentoalveolar Defects in the Hyp Mouse Model of X-linked Hypophosphatemia
H. Zhang et al.
JOURNAL OF DENTAL RESEARCH (2020)
Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score
Tom D. Thacher et al.
BONE (2019)
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
Erik A. Imel et al.
LANCET (2019)
Burosumab treatment of children with X-linked hypophosphataemic rickets
Rebecca J. Gordon et al.
LANCET (2019)
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Dieter Haffner et al.
NATURE REVIEWS NEPHROLOGY (2019)
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
Anthony A. Portale et al.
CALCIFIED TISSUE INTERNATIONAL (2019)
Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients
Sean DeLacey et al.
BONE (2019)
Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial
Karl L. Insogna et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
Michael P. Whyte et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey
Alison Skrinar et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2019)
Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale
Michael P. Whyte et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
Karl L. Insogna et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia
Michael Collins
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations
Douglas Chesher et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Thomas O. Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osteoporitin and the dento-osseous pathobiology of X-linked hypophosphatemia
Tchilalo Boukpessi et al.
BONE (2017)
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23
Erik A. Imel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Thomas O. Carpenter et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Anti-FGF-23 Neutralizing Antibodies Ameliorate Muscle Weakness and Decreased Spontaneous Movement of Hyp Mice
Yukiko Aono et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
A Clinician's Guide to X-Linked Hypophosphatemia
Thomas O. Carpenter et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets
Miroslav Zivicnjak et al.
PEDIATRIC NEPHROLOGY (2011)
Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status
Thomas O. Carpenter et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations
Erik A. Imel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice
Guoying Liang et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Hypophosphatemia: the common denominator of all rickets
Dov Tiosano et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2009)
Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia
Yukiko Aono et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Calcium and vitamin D: What is known about the effects on growing bone
Marie B. Demay et al.
PEDIATRICS (2007)
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Itaru Urakawa et al.
NATURE (2006)
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
T Shimada et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis
T Larsson et al.
ENDOCRINOLOGY (2004)
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX
SG Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets
O Mäkitie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Radiographic scoring method for the assessment of the severity of nutritional rickets
TD Thacher et al.
JOURNAL OF TROPICAL PEDIATRICS (2000)
分享论文
